PURPOSE: Use of enzalutamide has improved the treatment of advanced prostate cancer. However, resistance to enzalutamide can develop frequently in initial responders. This study aimed to test whether overexpression of IL-6 and constitutive activation of Stat3 in prostate cancer cells increase resistance to enzalutamide. EXPERIMENTAL DESIGN: Sensitivity of prostate cancer cells to enzalutamide was tested using cell growth assays and clonogenic assays. Quantitative reverse transcription-PCR, ELISA, and Western blotting were performed to detect expression levels of IL-6, c-Myc, survivin, and AR. Expression of Stat3 was downregulated using siRNA specific to Stat3. ChIP assay was performed to examine recruitment of AR to the PSA promoter. RESULTS: Prostate cancer cells expressing autocrine IL-6 are resistant to enzalutamide and autocrine IL-6 leads to constitutive activation of Stat3 and its target genes. Down regulation of Stat3 led to an increase in sensitivity of prostate cancer cells to enzalutamide. Overexpression of constitutively active Stat3 in prostate cancer cells induced resistance to enzalutamide treatment. Constitutively active Stat3 also enhanced the recruitment of AR to PSA promoter which could not be disrupted by enzalutamide. The Stat3 inhibitor AG490 reversed enzalutamide resistance in prostate cancer cells, while combination treatment with enzalutamide and AG490 significantly inhibited cell growth and induced cell apoptosis. CONCLUSIONS: This study demonstrates that the autocrine IL-6 pathway induces enzalutamide resistance in prostate cancer cells via the constitutive activation of Stat3. Co-targeting IL6-Stat3 pathway with enzalutamide may be utilized for treatment of advanced prostate cancer.
PURPOSE: Use of enzalutamide has improved the treatment of advanced prostate cancer. However, resistance to enzalutamide can develop frequently in initial responders. This study aimed to test whether overexpression of IL-6 and constitutive activation of Stat3 in prostate cancer cells increase resistance to enzalutamide. EXPERIMENTAL DESIGN: Sensitivity of prostate cancer cells to enzalutamide was tested using cell growth assays and clonogenic assays. Quantitative reverse transcription-PCR, ELISA, and Western blotting were performed to detect expression levels of IL-6, c-Myc, survivin, and AR. Expression of Stat3 was downregulated using siRNA specific to Stat3. ChIP assay was performed to examine recruitment of AR to the PSA promoter. RESULTS:Prostate cancer cells expressing autocrine IL-6 are resistant to enzalutamide and autocrine IL-6 leads to constitutive activation of Stat3 and its target genes. Down regulation of Stat3 led to an increase in sensitivity of prostate cancer cells to enzalutamide. Overexpression of constitutively active Stat3 in prostate cancer cells induced resistance to enzalutamide treatment. Constitutively active Stat3 also enhanced the recruitment of AR to PSA promoter which could not be disrupted by enzalutamide. The Stat3 inhibitor AG490 reversed enzalutamide resistance in prostate cancer cells, while combination treatment with enzalutamide and AG490 significantly inhibited cell growth and induced cell apoptosis. CONCLUSIONS: This study demonstrates that the autocrine IL-6 pathway induces enzalutamide resistance in prostate cancer cells via the constitutive activation of Stat3. Co-targeting IL6-Stat3 pathway with enzalutamide may be utilized for treatment of advanced prostate cancer.
Authors: Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono Journal: N Engl J Med Date: 2012-08-15 Impact factor: 91.245
Authors: Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda Journal: Cancer Cell Date: 2009-12-08 Impact factor: 31.743
Authors: Fernando DeMiguel; Soo Ok Lee; Wei Lou; Xiao Xiao; Beth R Pflug; Joel B Nelson; Allen C Gao Journal: Prostate Date: 2002-07-01 Impact factor: 4.104
Authors: Siting Feng; Qizhu Tang; Meng Sun; Jae Yeon Chun; Christopher P Evans; Allen C Gao Journal: Mol Cancer Ther Date: 2009-02-24 Impact factor: 6.261
Authors: Sonia A Duffy; Theodoros Teknos; Jeremy M G Taylor; Karen E Fowler; Mozaffarul Islam; Gregory T Wolf; Scott McLean; Tamer A Ghanem; Jeffrey E Terrell Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-01-08 Impact factor: 4.254
Authors: Chengfei Liu; Cameron M Armstrong; Wei Lou; Alan P Lombard; Vito Cucchiara; Xinwei Gu; Joy C Yang; Nagalakshmi Nadiminty; Chong-Xian Pan; Christopher P Evans; Allen C Gao Journal: Mol Cancer Ther Date: 2017-05-12 Impact factor: 6.261
Authors: Chengfei Liu; Cameron M Armstrong; Wei Lou; Alan Lombard; Christopher P Evans; Allen C Gao Journal: Mol Cancer Ther Date: 2016-10-28 Impact factor: 6.261
Authors: Vindhya Udhane; Cristina Maranto; David T Hoang; Lei Gu; Andrew Erickson; Savita Devi; Pooja G Talati; Anjishnu Banerjee; Kenneth A Iczkowski; Kenneth Jacobsohn; William A See; Tuomas Mirtti; Deepak Kilari; Marja T Nevalainen Journal: Mol Cancer Ther Date: 2019-09-23 Impact factor: 6.261
Authors: Chengfei Liu; Wei Lou; Yezi Zhu; Joy C Yang; Nagalakshmi Nadiminty; Nilesh W Gaikwad; Christopher P Evans; Allen C Gao Journal: Cancer Res Date: 2015-02-03 Impact factor: 12.701
Authors: Chengfei Liu; Wei Lou; Yezi Zhu; Nagalakshmi Nadiminty; Chad T Schwartz; Christopher P Evans; Allen C Gao Journal: Clin Cancer Res Date: 2014-04-16 Impact factor: 12.531
Authors: Theodoros Karantanos; Christopher P Evans; Bertrand Tombal; Timothy C Thompson; Rodolfo Montironi; William B Isaacs Journal: Eur Urol Date: 2014-10-08 Impact factor: 20.096